Sanofi and GSK grab largest Warp Speed deal yet, se­cur­ing $2.1B for a vac­cine that might come next year

Sanofi and Glax­o­SmithK­line have be­come the lat­est mem­bers of Op­er­a­tion Warp Speed, land­ing a $2.1 bil­lion con­tract to scale up man­u­fac­tur­ing for a vac­cine that is on track for com­ple­tion next year. The deal se­cures the US 100 mil­lion dos­es, with an op­tion for 500 mil­lion more.

It is the largest con­tract the White House has giv­en yet in its hunt to make 300 mil­lion dos­es of a vac­cine avail­able to the US pub­lic by Jan­u­ary, al­though Sanofi has not com­mit­ted to sup­ply vac­cines by that time, po­ten­tial­ly open­ing the door for oth­er de­vel­op­ers with longer de­vel­op­ment paths to gain fund­ing. The cash will help Sanofi scale the vac­cine, which com­bines their re­com­bi­nant DNA tech­nol­o­gy with GSK’s im­mune-boost­ing ad­ju­vant, to a bil­lion dos­es next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER